摘要 目的探讨长链非编码RNA(lncRNA)MBNL1-AS1的表达对急性髓系白血病(AML)预后的影响。方法纳入癌症基因组图谱数据库(TCGA)中2001年11月至2010年3月筛选出的125例AML患者,其中70例患者仅接受化疗,其余55例除化疗外还接受了异基因造血干细胞移植(allo-HSCT)。以lncRNA MBNL1-AS1的中位表达量为切点,将化疗组和移植组分别分为化疗高表达组(n=35)和化疗低表达组(n=35)、移植高表达组(n=28)和移植低表达组(n=27)进行预后比较。记录患者初诊时的临床特征,包括外周血白细胞计数(WBC),外周血和骨髓中肿瘤细胞百分比、FAB亚型和AML常见基因突变。对不同组别患者的无事件生存(EFS)率和总生存(OS)率进行分析。不同临床特征对AML患者预后的影响采用多因素COX回归模型进行分析。结果化疗低表达组患者EFS和OS分别为60.0%、8.6%,均低于高表达组的68.6%、34.3%(χ2=7.817、10.880,均P<0.01);移植高表达组与低表达组患者的EFS和OS差异均无统计学意义(均P>0.05)。COX多因素分析结果显示:高龄[EFS:HR(95%CI)=6.934(1.918~25.075),P=0.003;OS:HR(95%CI)=4.119(1.812~9.364),P=0.001]、lncRNA MBNL1-AS1低表达[EFS:HR(95%CI)=0.354(0.126~0.941),P=0.038;OS:HR(95%CI)=0.424(0.231~0.778),P=0.006]是化疗组患者预后不良的危险因素。结论长链非编码RNA MBNL1-AS1与AML的预后相关,其低表达是AML患者预后不良的危险因素。 Objective To explore the prognosis effect of the expression of long-chain non-coding RNA(lncRNA)MBNL1-AS1 on acute myeloid leukemia(AML)patients.Methods One hundred and twenty-five AML patients of the Cancer Genome Atlas(TCGA)from November 2001 to March 2010 were involved,including 70 patients who received chemotherapy only and other 55 patients treated with allogeneic hematopoietic stem cell transplantation(allo-HSCT)in addition to chemotherapy.According to the median expression of lncRNA MBNL1-AS1,patients of chemotherapy group were divided into high expression sub-group(n=35)and low expression sub-group(n=35),and patients of allo-HSCT group were also divided into high expression sub-group(n=28)and low expression sub-group(n=27)for prognosis analysis.Clinical characteristics at diagnosis,including peripheral white blood cell counts(WBC),blast percentages in peripheral blood and bone marrow(BM),French-American-British(FAB)subtypes and the frequencies of common genetic mutations in AML were described.The event-free survival(EFS)rate and overall survival(OS)rate of patients in different groups were analyzed,and the influence of the clinical characteristics of patients on the prognosis of AML was analyzed by COX multivariate analysis.Results In the chemotherapy group,patients with low lncRNA-MBNL1-AS1 expression had significantly lower EFS and OS(60.0%,8.6%)than patients with high lncRNA-MBNL1-AS1 expression(68.6%,34.3%)(χ2=7.817,10.880,all P<0.01).However,in the alloHSCT group,no significant differences were observed in EFS and OS of patients between high and low expression groups of lncRNA-MBNL1-AS1(all P>0.05).COX multivariate analysis confirmed that age≥60 years old(EFS:HR(95%CI):6.934(1.918-25.075),P=0.003;OS:HR(95%CI):4.119(1.812-9.364),P=0.001),and low expression of lncRNA MBNL1-AS1(EFS:HR(95%CI):0.354(0.126-0.941),P=0.038;OS:HR(95%CI):0.424(0.231-0.778),P=0.006)were independent risk factors for EFS and OS in the chemotherapy group.Conclusion The long-chain non-coding RNA MBNL1-AS1 is related to the pr
机构地区 广州医科大学附属第二医院血液科
出处 《中华医学杂志》 CAS CSCD 北大核心 2021年第13期934-938,共5页 National Medical Journal of China
基金 国家自然科学基金新疆联合基金(U1903117) 国家自然科学基金青年基金(81500118)。
分类号 R73 [医药卫生—肿瘤]
